

# Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection *In Vitro*

Anne Sadewasser,<sup>1</sup> Erik Dietzel,<sup>2</sup> Sven Michel,<sup>1</sup> Michael Klüver,<sup>2</sup> Markus Helfer,<sup>1</sup> Tamara Thelemann,<sup>1</sup> Richard Klar,<sup>1</sup> Markus Eickmann,<sup>2</sup> Stephan Becker,<sup>2</sup> and Frank Jaschinski<sup>1</sup>

<sup>1</sup>Secarna Pharmaceuticals, GmbH & Co. KG, 82152 Planegg/Martinsried, Germany; <sup>2</sup>Deutsches Zentrum für Infektionsforschung (DZIF), Institut für Virologie, Philipps-Universität, 35043 Marburg, Germany

**Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus. Here, we selected the host factor Niemann-Pick C1 (NPC1), which has been shown to be essential for Ebola virus entry into host cytoplasm, as a therapeutic target for suppression by locked nucleic acid-modified antisense oligonucleotides. Screening of antisense oligonucleotides in human and murine cell lines led to identification of candidates with up to 94% knockdown efficiency and 50% inhibitory concentration (IC<sub>50</sub>) values in the submicromolar range. Selected candidate oligonucleotides led to efficient NPC1 protein knockdown *in vitro* without alteration of cell viability. Furthermore, they did not have immune stimulatory activity in cell-based assays. Treatment of Ebola-virus-infected HeLa cells with the most promising candidates resulted in significant (>99%) virus titer reduction, indicating that antisense oligonucleotides against NPC1 are a promising therapeutic approach for treatment of Ebola virus infection.**

## INTRODUCTION

Ebola virus (EBOV), as well as four other filoviruses—Bundibugyo virus (BDBV), Sudan virus (SUDV), Marburg virus (MARV), and Ravn virus (RAVV)—are causative agents of severe disease in humans, such as severe hemorrhagic fever, and are often associated with high morbidity and mortality rates.<sup>1–3</sup> These viruses belong to the family *Filoviridae* of non-segmented negative-strand RNA viruses and are biosafety level 4 pathogens transmitted by contact with body fluids, fomites, and droplets from infected patients. Filoviruses are considered a significant threat to public health and global security because of their pandemic potential and the risk of being used as a bio-weapon.<sup>1,4–6</sup> Therefore, accelerated efforts in the development of therapeutics is a key objective in the filovirus research community, especially since the 2013–2016 EBOV disease (EVD) epidemic in Western Africa. No vaccines or therapeutic agents with final US Food and Drug Administration (FDA) approval are currently available, and supportive care remains the standard for Ebola virus disease treatment. However, to reduce EBOV spread and the pandemic risk of the current outbreak in Democratic Republic of the Congo (750

confirmed cases and 449 confirmed deaths, as of February 9, 2019) (<https://www.who.int/ebola/situation-reports/drc-2018/en/>) use of rVSV-ZEBOV Ebola vaccine, as well as antiviral drugs and antibodies against EBOV, have been temporarily approved (<https://www.who.int/ebola/drc-2018/faq-vaccine/en/>, <https://www.who.int/ebola/drc-2018/treatments-approved-for-compassionate-use/en/>).

Filovirus particles have a uniform diameter of 80 nm and variable lengths. A single transmembrane glycoprotein (GP), consisting of two subunits, GP1 and -2, is inserted into the virus envelope as a trimeric complex. GP mediates cell attachment and endocytosis by binding to attachment proteins of the host cell.<sup>7,8</sup> In late endosomes, the host cysteine proteases cathepsin-B and -L cleave and remove large C-terminal regions of the GP1 subunit,<sup>8,9</sup> thereby unmasking a binding site for the host factor Niemann-Pick C1 (NPC1). This cholesterol transport protein has been shown to be an essential host factor<sup>10,11</sup> and endosomal entry receptor for filoviruses.<sup>12,13</sup> In cooperation with Niemann-Pick C2 (NPC2), NPC1 is an endosomal transmembrane protein that mediates transport of luminal cholesterol across the endosomal and lysosomal membrane for dispersal to other cellular compartments.<sup>14,15</sup> Loss-of-function mutations in *NPC1* or *NPC2* cause a rare and often fatal hereditary neurovisceral disorder in humans.<sup>16,17</sup> Over time, patients with NPC disease accumulate cholesterol and glycosphingolipids in various tissues and organs, leading to neurological dysfunction and organ failure. Herbert et al.<sup>18</sup> demonstrated that *Npc1*-deficient mice are completely protected from EBOV infection and free of replicating virus. These results strongly implicate the NPC1 protein as a direct mediator of filovirus infection *in vivo*. It has been reported that NPC1 inhibition by U18666A, an amphipathic steroid, as well as the EBOV-specific antiviral compound 3.47 significantly inhibit filovirus replication by interfering with viral entry<sup>10,11</sup> *in vitro* and *in vivo*.<sup>18</sup> However, both compounds have not yet reached clinical trials.

Received 14 September 2018; accepted 10 April 2019;  
<https://doi.org/10.1016/j.omtn.2019.04.018>.

**Correspondence:** Frank Jaschinski, PhD, Secarna Pharmaceuticals, GmbH & Co. KG, 82152 Planegg/Martinsried, Germany.  
**E-mail:** [frank.jaschinski@secarna.com](mailto:frank.jaschinski@secarna.com)



**Table 1. Sequence and Modification of the ASOs 05HM, 28H, and Neg1**

Name	mRNA Binding Sequence	Position	Length	Sequence
05HM	GGAGAGTGTGGAATTGC	359	17	+G*+C*+A*A*T*T*C*C*A*C*A*C*T*T*C*+T*+C*+C
28H	AGCGCGAACGGCTTCTA	4,086	17	+T*+A*+G*A*A*G*C*C*G*T*T*C*G*C*+G*+C*+T
Neg1	N/A	N/A	18	+C*+G*+T*T*T*A*G*G*C*T*A*T*G*T*A*+C*+T*+T

Depicted are name of ASO, mRNA binding sequence, position on mRNA, ASO length as well as ASO sequence and modification: LNA (+) and/or phosphorothioate (\*). Human-specific ASOs (H) as well as cross-reactive ASOs targeting both, human and murine *NPC1* (HM), were selected.

Besides small molecules and therapeutic antibodies, oligonucleotide-based gene expression inhibitors have developed into fully accepted therapeutics. The majority of compounds progressing through clinical trials<sup>19–21</sup> are either antisense oligonucleotides (ASOs), comprising single-stranded DNA-like molecules that recruit endogenous RNase H for target mRNA degradation or small-interfering RNAs (siRNAs) that work through the RNA-induced silencing complex (RISC). ASOs typically have a length of 12–21 nucleotides (nt). In our study, nucleotides were joined via phosphorothioate (PTO) linkages. The phosphorothioate linkage substitutes a sulfur atom for a non-bridging oxygen. This modification renders the internucleotide bond resistant to nuclease degradation and enhances plasma-protein binding while retaining the ability to direct RNase H activity in the cell.<sup>22,23</sup> In addition, ribose moieties in the flanks of the oligonucleotide are modified by an extra bridge connecting the 2' oxygen and 4' carbon. This modification locks the conformation of the ribose, conferring high affinity to the RNA. Therefore, this modification is termed the “locked nucleic acid (LNA) modification.”<sup>24,25</sup>

Here, we demonstrate the potency of LNA-containing ASO (LNA-ASO) molecules targeting mRNA of the host factor *NPC1*, which is essential for filovirus replication. We show that *NPC1*-specific ASOs efficiently reduce viral replication in cultured cells without affecting cell viability or inducing immune-stimulatory responses.

## RESULTS

### Selection of ASOs Targeting Host Factor Niemann-Pick C1

*NPC1*-specific 15-, 16- and 17-mer ASOs were selected based on human NCBI reference sequence (accession number GenBank: NM\_000271.4) (Table S1). The main criterion for sequence selection was selectivity, to avoid undesired off-target effects. Several sequences were completely cross-reactive to murine *Npc1*, several had one or more mismatches. ASO length, LNA modification pattern, and localization of ASO binding sequence on human *NPC1* mRNA are depicted in Tables 1 and S1 and Figure 1.

### *NPC1* ASOs Efficiently Reduce *NPC1* mRNA Expression in Human and Murine Cell Lines


The *in vitro* activity of the 36 *NPC1*-specific ASOs was evaluated in two human and one murine cell line endogenously expressing *NPC1* mRNA. After treating these cells with LNA-ASO without using a transfection reagent,<sup>26</sup> the level of *NPC1* mRNA was measured after 3 days of treatment. Human HeLa and THP-1 cells were used as cell lines for screening, as both cell lines are susceptible to EBOV infec-

tion. *NPC1*-specific ASOs led to reduced *NPC1* mRNA expression levels in both human cell lines with correlating efficacies (Figure 2A). As expected, cross-reactive ASOs having full complementarity to both human and murine *NPC1* mRNA were more efficient in murine 4T1 cells than ASOs that are human-specific and have mismatches to the murine target (Figure 2B). Therefore, an increased number of mismatches of the human-specific ASOs to the murine *Npc1* sequence resulted in decreased efficacy in murine 4T1 cells (Figure 2B). In all three cell lines, the human-mouse cross-reactive ASO 05HM was the most efficient candidate with 95% (HeLa), 79% (THP-1), and 98% (4T1) *NPC1* mRNA knockdown, while the human-specific ASOs 28H and 29H were among the most potent ASOs in human cells, but had poor activity in murine cells (Figure 2). To test dose-dependence of effects, HeLa and 4T1 cells were exposed to increasing concentrations of ASO 05HM and 28H. Endogenous mRNA levels were evaluated after 3 days of treatment with ASOs, and the 50% inhibitory concentration (IC<sub>50</sub>) for the inhibition of *NPC1* expression was determined (Figures 3A–3C). As already indicated by the aforementioned screening results, ASO 05HM (IC<sub>50</sub> = 668 nM) was more potent in the HeLa cells than was ASO 28H (IC<sub>50</sub> = 2,781 nM; Figures 3A and 3B). In the murine cell line 4T1, the cross-reactive ASO 05HM was even more effective (IC<sub>50</sub> = 457 nM; Figure 3C). Notably, treatment with ASOs did not affect cell viability at any concentration (Figure 3D). Using immunoblot analysis, knockdown efficacy on protein level was evaluated and confirmed in HeLa cells, treated twice for 3 days with ASO 05HM and 28H (Figure 3E). Both ASOs clearly reduced *NPC1* protein levels compared with untreated cells or with cells treated with control Neg1 that is not complementary to any human or murine RNA (Figure 3E).<sup>27</sup> Again, treatment of HeLa cells with ASO 05HM resulted in a more pronounced *NPC1* knockdown than incubation with ASO 28H (Figure 3E).

Taken together, these data demonstrate the potential of the *NPC1*-specific LNA-ASOs for efficient knockdown of *NPC1* gene expression in human and murine cell lines.

### Selected *NPC1*-Specific LNA-ASOs Do Not Cause Adverse Effects *In Vitro*

Immune activation leading to cytokine release is characteristic of therapeutic oligonucleotides, either as an unwanted side effect or intended pharmacology. This immune activation is mediated by pattern recognition receptors, such as the Toll-like receptors (TLRs). Binding of immune stimulatory ligands, e.g., bacterial DNA or immune stimulatory oligonucleotides, with or without nonmethylated CpG



**Figure 1. ASO Distribution on Human NPC1 mRNA**

All ASOs are depicted according to their location on the human *NPC1* mRNA along the x axis. Distinct exons (red) and UTRs (green) are shown in the bottom part of the figure. The lengths of the ASOs are indicated on the y axis.

dinucleotides,<sup>28</sup> results in TLR activation. As immune activation can lead to a severe, possibly life-threatening, condition of excessive cytokine release,<sup>29</sup> the selected LNA-ASOs 05HM and 28H were analyzed for their potential to activate TLR9 and to induce cytokine release in human cells, enabling a safety assessment for future clinical studies.

To assess the potential of *NPC1*-specific ASOs to activate TLR9-mediated signaling, an HEK-Blue hTLR9 SEAP reporter assay was used to measure activation of nuclear factor-kappa light-chain enhancer of activated B cells (NF- $\kappa$ B) induced by TLR9. In contrast to the human TLR9 agonist CpG ODN2006, neither ASO 05HM nor ASO 28H triggered human NF- $\kappa$ B activation (Figure 4A). Murine Nf-kb was also not induced by treatment with cross-reactive ASO 05HM tested in stably transfected HEK-mTlr9\_Nf-kb-LUC cells (Figure 4B), whereas the murine Tlr9 agonist ODN1668 induced a considerable dose-dependent response.

TLRs are expressed by numerous cells of the immune system, such as B lymphocytes, monocytes, natural killer (NK) cells, keratinocytes, melanocytes, and plasmacytoid dendritic cells (pDCs). The peripheral blood mononuclear cell (PBMC)-based assay is well established for determination of immune activation by different drugs, including TLR ligands and oligonucleotides.<sup>28,30,31</sup> Here, PBMC isolated from leukocytes preparations of three different donors were used. In contrast to pattern recognition receptor agonists, ODN2006, lipopolysaccharide (LPS), or immune stimulatory CD3/CD28/CD2, the ASO 05HM failed to trigger a cytokine response (Figure 5).

These data support that the most potent ASOs, 05HM and 28H, do not trigger a host innate immune response.

#### ***NPC1*-Specific LNA-ASOs Efficiently Inhibit EBOV Replication *In Vitro***


LNA-ASOs 05HM and 28H were then tested for antiviral activity during EBOV infection. To ensure efficient downregulation of endosomal NPC1 protein (Figure 3E), HeLa cells were treated twice with ASO 05HM and 28H for 3 days. Then, cells were infected with EBOV at an MOI of 0.01 and incubated for 24 h in medium contain-

ing the respective ASOs. Compared to untreated cells, *NPC1* mRNA was significantly reduced (by about 89% [05HM] and 80% [28H]; Figure 6A), whereas EBOV virus genome copies were decreased by about 99% (05HM) and 98% (28H), 1 day after infection, as quantified by qPCR (Figure 6B). Treatment with the control oligonucleotides Neg1 (Figure 6A; Figure S2A), Neg1B, or S5 (Figure S2A) did not reduce *NPC1* mRNA levels. However, EBOV replication was also decreased (by about 62% [Neg1, Figure 6B] and 70% [Neg1B and S5; Figure S2B]), most likely due to the backbone-mediated effects of phosphorothioate-modified oligonucleotides (Figure 6B; Figure S2A).

Treatment with phosphorothioate-modified non-targeting oligonucleotides reduced EBOV replication by 62–70% *in vitro*. Furthermore, oligonucleotides specifically targeting NPC1, an essential receptor of EBOV cell entry, led to a more potent inhibition of EBOV replication—up to 99%.

#### **DISCUSSION**

EBOV causes a severe, often fatal illness in humans, is transmitted to people from wild animals, and spreads in the human population through human-to-human transmission.<sup>32</sup> Case fatality rates of Ebola virus disease have varied from 25% to 90% in past outbreaks, with an average of around 50%.<sup>33,34</sup> There are two distinct paths for potential EBOV treatments: post-exposure prophylaxis and treatment of symptomatic patients. Both have different challenges, but a common strategy may be to limit virus replication, to allow the adaptive and innate immune systems time to fight the infection.<sup>35,36</sup> A limitation for ASO-based antiviral strategies directly targeting the virus may be the RNase H1-dependent mode of action of gapmer ASOs. Filoviruses replicate in the host cytoplasm and do not require the nucleus.<sup>37</sup> However, the cellular compartment of ASO-mediated RNA degradation is a controversial issue within the ASO community.<sup>38–41</sup> We and others showed that ASOs targeting EBOV mRNA could efficiently block viral transcription or replication in cell-free<sup>42</sup> and reporter gene assays (Figures S1A and S1B). In reporter-based assays, transcription of the reporter genes takes place in the nucleus. However, EBOV-specific ASOs were not capable of inhibiting viral propagation in Huh7 cells, with or without the use of a transfection reagent (Figures S1C and S1D). These results indicate, that the predominant location of RNase H1-mediated target RNA degradation is the nucleus that is, as previously mentioned, bypassed during EBOV replication. The use of ASO approaches aimed at sterically blocking viral translation in the cytoplasm could avoid this issue. However,



**Figure 2. Screening of NPC1-Specific LNA-ASOs in Human and Murine Cell Lines**

(A and B) Human HeLa and THP1 cells (A) as well as murine cell line 4T1 (B) were treated with 10  $\mu$ M of ASOs. After 3 days cell lysates were used to determine NPC1 and HPR1 mRNA levels. (A) Shown is the correlation of residual NPC1 mRNA expression (means and SD of triplicate wells) after treatment in HeLa (x axis) versus THP1 cells (y axis). Values were normalized to HPR1 and relative to the untreated control (set as 1; empty square). ASO 05HM is indicated as a filled diamond, ASO 28H as a filled triangle, Neg1 as an empty circle, and other NPC1-specific ASOs as filled circles. (B) Residual Npc1 mRNA expression in 4T1 cells after treatment with respective NPC1-specific ASOs or negative control Neg1. Values were normalized to Hprt1 and are shown relative to the untreated control (set as 1). Error bars show SD (triplicate wells). The number of mismatches to murine Npc1 sequence of human specific ASOs (H) are shown in different colors and patterns.

translation-blocking approaches are much less efficient compared to RNase-H1-dependent mechanisms. Whereas one translation-blocking ASO-molecule is needed to repress translation of one target mRNA molecule, one RNase H1-dependant ASO could mediate degradation of many individual RNA molecules. Therefore, much higher doses would be necessary for a translation-blocking approach in the cytoplasm. The antiviral efficacy of translation-blocking approaches was suggested by Chery et al.<sup>42</sup> indirectly by use of reporter-based assays. However, direct evidence for antiviral effects such as copy number determination of an EBOV isolate after ASO treatment is missing. A fundamental disadvantage of approaches targeting EBOV directly is the error-prone viral polymerase of RNA viruses that enables incorporation of the mutations that facilitate resistance against antiviral drugs. Furthermore, antiviral approaches have not been capable of overcoming strain-specific differences, so far. Although the efficacy of antibody cocktails, such as ZMapp, for EBOV in nonhuman primates is clear, a future challenge will be to identify similar treatments for other filoviruses.<sup>43</sup>


For the aforementioned reasons, targeting an essential human host factor for viral replication may be one of the most promising approaches for fighting EBOV. An essential host factor for filovirus replication *in vitro* and *in vivo* is the cholesterol transport protein NPC1. This endosomal entry receptor has been shown to mediate cytoplasmic release of viral ribonucleoproteins,<sup>10,13</sup> making it an ideal target for blocking filovirus replication.

Various small molecule therapeutics against host factor NPC1 have been described, some with demonstrated efficacy against filovirus replication in mice.<sup>43</sup> However, those molecules targeting NPC1 did not reach clinical trials, so far, probably because of the described toxic effects<sup>44</sup> or the need for further mechanistic characterization, as well as improvement of compounds.<sup>43</sup> The limited success of the available NPC1 inhibitors in protecting mice from EBOV challenge highlights the need for new molecules or approaches to target NPC1 *in vivo*.<sup>18</sup>

A unique advantage of ASOs targeting essential host factors for filovirus replication, particularly in the context of emergency prophylactic or post-exposure therapeutics, is their target specificity, cost-effectiveness, and fast generation. Mode of action, uptake, bio-distribution, pharmacokinetics, and safety issues have been extensively studied.<sup>24,26,45–50</sup>

In the present study, a total of 36 ASOs was designed for the initial screen broadly covering the NPC1 mRNA sequence. Fifteen-, 16-, and 17-mer ASOs were tested, and two ASOs, comprising 17 nt, were selected for further experiments. As recommended by the Oligonucleotide Safety Working Group,<sup>51</sup> an extensive *in silico* approach was used to avoid suppression of off-target genes. The bioinformatic analysis revealed no perfect match to any exonic or intronic off-target sequence. Even allowing one mismatch, still no off-target hit was detected in the NCBI RefSeq data base. This off-target characteristic is well in the range of the characteristic of other ASOs recently published in the field.<sup>42,52</sup> This should also decrease risk of generation of ASO-generated RNA fragments, which, as Dieckmann et al.<sup>45</sup> speculated, could cause toxicity.

ASOs have been repeatedly described to stimulate immune activation.<sup>22,53–56</sup> Reasons for immune stimulatory activities were reported to be nonmethylated CpG dinucleotides within the oligonucleotide sequence, as well as the stabilizing phosphorothioate backbone.<sup>57–59</sup> Studies using Tlr9-deficient mice demonstrated that this Tlr subtype is essential for the effects that are mediated by bacterial DNA or CpG oligonucleotides.<sup>60</sup> Since expression, ligand preference, and function of pattern-recognition receptors is highly species specific,<sup>61</sup> cytokine release in humans is hard to predict in animal studies. The human TLR9 is expressed in B cells and pDCs.<sup>61–63</sup> Both cell types are stimulated by CpG oligonucleotides to upregulate cell surface costimulatory molecules and to secrete a variety of cytokines.<sup>64,65</sup> These effects can lead to indirect activation of other cell populations, such as monocytes and NK or T cells.<sup>65</sup> The *in vitro* TLR9 assays as well as the PBMC *ex vivo* test used in this study are therefore helpful in




**Figure 3.  $IC_{50}$  Determination and Protein Knockdown Efficacy of ASOs 05HM and 28H**

(A–D) HeLa and 4T1 cells were used to generate dose-response curves by treating them with different concentrations of ASO 05HM (A and C) and 28H (B), respectively. On day 3, cell viability was determined using a CellTiter Blue Assay Kit (D). Then, cells were lysed and *NPC1* and *HPRT1* mRNA levels were determined. Values were normalized to the housekeeping gene *HPRT1* and are shown relative to untreated cells (set as 100).  $IC_{50}$  values were calculated using Prism 6 (GraphPad Software). Data are means and SD (triplicate wells). (E) HeLa cells were treated twice for 3 days with 10  $\mu$ M ASO 05HM, 28H, negative control oligonucleotide Neg1 or were left untreated. On day 6, cells were lysed, and lysates were analyzed for NPC1 and Actin protein expression using SDS-PAGE and immunoblot analysis in duplicate wells.

deselecting ASOs with immune stimulatory potential early in the screening and compound characterization process, to prevent unexpected harmful effects in clinical development. In contrast to the CpG oligonucleotides ODN2006 and ODN1668, which were used as positive controls, both of the selected *NPC1*-targeting ASOs 05HM and 28H activated neither human nor murine TLR9 (Figure 4), nor did ASO 05HM stimulate cytokine release in treated PBMCs (Figure 5). These results are in line with the findings of Vollmer and colleagues,<sup>28</sup> who demonstrated that LNA modification of ASOs significantly decreases the immune stimulatory effects of ASOs. Our bioinformatics analysis enabled the selection of cross-reactive ASOs that target human as well as murine *NPC1* mRNA for screening in hu-

man and murine cell lines. Again, the benefit of our rational ASO design was confirmed, as cross-reactive ASOs were effective in both species *in vitro* (Figure 2). As expected, a decreased knockdown of murine *Npc1* by human-specific ASOs with no 100% complementarity to the murine mRNA was observed in murine cells. Thereby, a higher number of mismatches to the murine *Npc1* sequence was associated with decreased activity in murine cells (Figure 2B). In *Npc1*<sup>-/-</sup> mice, it was previously demonstrated that the *Npc1* protein acts as a direct mediator for EBOV infection *in vivo*.<sup>18</sup> Since ASO 05HM targets human and murine *NPC1*, it is also a suitable tool for testing *in vivo* efficacy against different filovirus strains in mice.



**Figure 4. NPC1-Specific ASOs 05HM and 28H Did Not Activate TLR9 Signaling**

(A) HEK-Blue hTLR9 cells were treated with ODN2006 or LNA-ASOs 05HM and 28H, respectively, with the indicated concentrations. After 20 h SEAP reporter activity was measured at 620 nm, using a microplate reader. (B) HEK cells expressing a mouse Tlr9 Nf- $\kappa$ B luciferase reporter plasmid were treated with the indicated concentrations of ODN1668 or LNA-ASO 05HM. After 20 h, the cells were treated with ONE-Glo EX reagent, and luminescence was measured at 560 nm. Values were normalized to untreated cells and are means with SD (triplicate wells).

*NPC1* ASO screening in two different human cell lines resulted in strong correlation of ASO activity, which enabled reliable selection of candidate ASOs. Consistently, ASO 05HM was the most effective candidate during single-dose screens in one murine and two human and cell lines (Figure 2), during IC<sub>50</sub> determination (Figures 3A–3C), protein knockdown (Figure 3E), and the infection assay in HeLa cells (Figure 6). All experiments were performed by using a method called “gymnosis” without using a transfection reagent.<sup>26</sup> The pattern of gene silencing of *in vitro* gymnastically delivered oligonucleotides correlates particularly well with *in vivo* silencing and is therefore of particular significance for drug discovery.<sup>26</sup> Recently, Chery and colleagues<sup>42</sup> also reported on efficient knockdown of *NPC1* by use of target-specific ASOs. However, these ASOs were delivered into cells using lipofection and may have divergent characteristics *in vivo*.

Macrophages, monocytes, and dendritic cells are the primary target cells during acute EBOV infection, and several organs, such as liver, kidneys, and spleen, show high viral loads during the course of infection.<sup>66–69</sup> These cell types and organs are also good targets for phosphorothioate-modified ASOs which have a preferred biodistribution to kidney, liver, and immune cells and are not capable of crossing the blood-brain barrier.<sup>46</sup> Therefore they cannot affect the transport of cholesterol in neurons within the CNS, which could cause a Niemann-Pick disease-like phenotype.


Treatment with *NPC1*-specific ASO resulted in significantly decreased EBOV replication (>99%; Figure 6B). Similar results were obtained by Chery and colleagues<sup>42</sup> by use of a VSVluc-EboV GP reporter virus. Reduced luciferase expression up to 80% was detected after transfection of HeLa cells with an *NPC1*-specific ASO. However, neither was the immune stimulatory potential of the selected ASO tested nor was a negative control ASO included to test for potential unspecific effects. Therefore, whether the observed decrease in reporter virus replication is a backbone-mediated or a specific effect caused by *NPC1* knockdown cannot be distinguished.<sup>42</sup> In the present study, the control oligonucleotides clearly diminished the amount of EBOV genome copies 24 h after infection, though to a lesser extent (Figure 6B; Figure S2B). In addition to their sequence-specific functionality, single-stranded oligonucleotides are polymers with polyanionic characteristics that are largely conserved, regardless of their nucleotide sequence. Phosphorothioation of oligonucleotides confers increased hydrophobicity and has been shown to specifically mediate

antiviral activity in a manner independent of the increased nuclease stability present with this modification.<sup>70,71</sup> Phosphorothioates with broad-spectrum activity against viral and other infectious diseases are also called “nucleic acid polymers” (NAPs).<sup>72</sup> The structure-function relationship of the antiviral activity of NAPs, as well as their molecular mechanism of action, was first elucidated in a study describing the specific antiviral effects of NAPs during the entry of HIV-1.<sup>71</sup> In this study, the entry inhibition effect of NAPs was shown to be independent of sequence, but dependent on size.<sup>71</sup> A large amphipathic protein domain in the viral gp41 glycoprotein is required for interaction with NAPs and conserved in class I fusion GPs from many other viruses susceptible to antiviral polymers. Following on the findings in the initial study in HIV-1, NAPs were subsequently shown to have the same sequence-independent and phosphorothioate as well as length-dependent antiviral effects in other viruses with class I fusion GPs, including herpesviruses, cytomegalovirus, influenza virus, and lymphocytic choriomeningitis virus.<sup>73–77</sup> Meanwhile, the company Replicor develops antiviral drug candidates against hepatitis B and D viruses based on the mechanism by which NAPs inhibit viral propagation.

Interestingly, EBOV GP, which is required for virus entry into the host cell, is also a class I fusion protein.<sup>78</sup> Keeping this fact in mind, it may be reasonable that, to some extent, phosphorothioated oligonucleotides inhibit EBOV replication, independent of sequence.

These findings could explain the 62–70% reduction of viral replication detected with control phosphorothioates that did not reduce *NPC1* mRNA levels (Figures 6A and 6B; Figures S2A and S2B). However, the specific oligonucleotides 05HM and 28H significantly reduced the EBOV titer after 24 h of infection by 97%–99% compared to non-treated cells (Figure 6B; Figure S2B). This result strengthens our hypothesis that RNase H1-mediated targeting of an essential host factor for virus entry has an additional effect of solely backbone-mediated reduction of EBOV entry, thereby vastly improving therapeutic antiviral potential.

Taken together, the findings in this study demonstrate that knockdown of intracellular receptor *NPC1* by target-specific ASOs is a promising approach for treatment of EBOV infection. Our selected human-mouse cross-reactive *NPC1*-specific ASO may be used in future studies to further investigate the efficacy of *Npc1*-specific ASO against EBOV in mouse models.



**Figure 5. NPC1-Specific ASO 05HM Did Not Stimulate Cytokine Release from Treated PBMCs**

(A–C) PBMCs from three different donors were treated with oligonucleotides and immune stimulatory agents (each condition in triplicate wells), with the indicated concentrations. The third day after treatment, supernatants were harvested and used for determination of cytokine release using ELISA: (A) IFN $\gamma$ , (B) IL6, and (C) TNF $\alpha$ . Values were displayed as fold changes compared to untreated. Means and SDs were also indicated. ANOVA test was used to test for significant differences and p values were determined using Dunnett's test in GraphPad Prism 7.04 Software.

The main criterion for the selection process was the absence of a perfect match to any human or mice off-target mRNA or intron sequence. In addition, only a limited number of off-target matches allowing up to three mismatches were tolerated. As recommended by the distributor (<https://www.qiagen.com/de/shop/pcr/primer-sets/custom-lna-oligonucleotides/?akamai-feo=off&clear=true#productdetails>), sequences containing a triple C or triple G pattern were avoided. The melting temperatures of the reverse complements of the remaining sequences were determined *in silico*, considering the effects of LNA modifications. The typical LNA-gapmer format of three modifications at each side<sup>80,81</sup> was optimized, if there were strong deviations from the internally defined range of an appropriate melting temperature. In the first screen, 23 sequences showing a perfect match to human and mice NPC1 mRNA and 13 sequences specific only to the human mRNA were used to design ASOs containing phosphorothioate bonds and the optimal LNA pattern.

For screening, IC<sub>50</sub> determination and analysis of protein knockdown, 40 nmol of ASOs were syn-

thesized by Eurogentec (Cologne, Germany). After selection of two of the most effective candidates, 5 mg of the ASOs 05HM and 28H were purchased from Exiqon (Copenhagen, Denmark) for *in vitro* infection assays. Control oligonucleotides Neg1 and S5 were synthesized by Exiqon (Copenhagen, Denmark), and negative control oligonucleotide Neg1b was purchased from Axolabs (Kulmbach, Germany). ASOs were purified by reverse-phase high-performance liquid chromatography (HPLC) and subsequently lyophilized. After receiving the ASOs, they were solubilized in diethyl-pyrocarbonate (DEPC)-treated H<sub>2</sub>O to a concentration of 1 mM.


#### Screening of NPC1-Specific ASOs

HeLa (ACC 57; DSMZ, Braunschweig, Germany), THP-1 (ACC 16; DSMZ), and 4T1 (CRL-2539; ATCC-LGC Standards, Wesel, Germany) cells were cultured in DMEM GlutaMAX (32430027; Gibco,

## MATERIALS AND METHODS

### Selection of NPC1-Specific ASOs

The human mRNA sequence of NPC1, as defined by NCBI accession number GenBank: NM\_000271.4, was taken as a basis to design the ASOs. For this sequence (4,827 bp) the possible 15-, 16-, and 17-mer sequence fragments were extracted. All 14,442 fragments were tested for specificity against the complete NCBI RefSeq (<https://www.ncbi.nlm.nih.gov/refseq/>) and ENSEMBL (<http://www.ensembl.org/>) databases, by using PatMaN.<sup>79</sup> Possible matches, including up to three mismatches against any mRNA (RefSeq) or any intron (ENSEMBL), were collected to enable a filtering of those fragments showing the highest specificity. As a cross-reactivity to mice was additionally desired, the sequences were tested against all mouse sequences of both databases, as well.



**Figure 6. NPC1-Specific ASOs 05HM and 28H Specifically Inhibit EBOV Replication**

(A and B) HeLa cells pretreated with the respective ASO were infected with EBOV at an MOI of 0.01. At 1 day after infection (p.i.), *NPC1* (A) and EBOV (B) levels were quantified by RT-qPCR and normalized to the internal control  $\alpha$ -tubulin. Shown is the fold change compared to untreated control (set at 100), which was calculated using the  $2^{-\Delta\Delta Ct}$  method. Error bars show SD ( $n = 3$ , each in duplicate). Duplicates are labeled with identical symbol shapes. ANOVA was used to test for significant differences and p values were determined using Dunnett's test, in GraphPad Prism 7.04 Software. See also Figure S2.

Life Technologies, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS; 10270106; Gibco), 1 mM sodium pyruvate (11360070; Gibco), and  $1\times$  antibiotic-antimycotic (15240062; Gibco).

The cells were detached using trypsin (25200056; Gibco), seeded into 96-well plates at 6,000 (HeLa), 20,000 (THP-1), and 5,000 (4T1) cells per well and treated with the *NPC1* ASO compounds on day 0. Treatments were done at a final concentration of 10  $\mu$ M with triplicate experiments for each compound. A control oligonucleotide, Neg1, was used at a final concentration of 10  $\mu$ M with triplicate experiments. On day 3, cells were lysed, and mRNA levels were measured according to the manufacturers' instructions, using QuantiGene Singleplex Gene Expression Assay (QS0011; Life Technologies, Darmstadt, Germany) and the following probe sets: human probe sets specific for *NPC1* (SA-10502; Life Technologies) and the housekeeping gene *HPRT1* (SA-10030; Life Technologies) or probe sets specific for murine *Npc1* (SB-12805; Life Technologies) and *Hprt1* (SB-15463; Life Technologies).

Residual *NPC1* mRNA expression levels were calculated by comparing the *NPC1* values normalized to *HPRT1* in the ASO-treated samples with that measured in the untreated control.

#### IC<sub>50</sub> Determination

HeLa and 4T1 cells were used to generate dose-response curves by treating them with different concentrations (5,000 nM, 1,000 nM, 200 nM, 40 nM, 8 nM, and 1.6 nM) of ASO 05HM (4T1; HeLa) and 28H (HeLa). On day 3 after treatment, cell viability was determined using the CellTiter-Blue Assay (G8081; Promega, Mannheim, Germany) according to the manufacturer's instructions. Afterwards, the cells were lysed, and mRNA levels were measured according to the manufacturers' instructions, using the QuantiGene Singleplex Gene Expression Assay (QS0011; Life Technologies) and the following probe sets: human probe sets specific for *NPC1* (SA-10502; Life Technologies) and the housekeeping gene *HPRT1* (SA-10030; Life Technologies) or probe sets specific for murine *Npc1* (SB-12805; Life Technologies) and *Hprt1* (SB-15463; Life Technologies). Values were normalized to the housekeeping gene *HPRT1* and cell control (untreated cells). IC<sub>50</sub> values were calculated using Prism 6 (GraphPad Software).

#### Immunoblot Analysis

HeLa cells were seeded into 12-well plates at 75,000 cells per well and treated twice with 10  $\mu$ M ASO 05HM and 28H for 3 days each. On day 6, cells were lysed using 100  $\mu$ L RIPA buffer (89900; Thermo Scientific, Life Technologies) per well supplemented with Halt Protease Inhibitor Cocktail (1861278; Thermo Scientific). Samples were prepared for SDS-PAGE using  $4\times$  Laemmli sample buffer (161-0747; Bio-Rad Laboratories, München, Germany) and proteins were separated using Mini-Protean TGX™ Precast Gels (456-8025; Bio-Rad Laboratories), Precision Plus Protein Western C Standard (161-0376; Bio-Rad Laboratories), and  $1\times$  Tris/glycine/SDS (TGS; 161-0732; Bio-Rad Laboratories) according to the manufacturer's instructions. Polyvinylidene fluoride (PVDF) membrane (162-0177; Bio-Rad Laboratories) was activated in 100% ethanol (5054.4; Carl Roth, Karlsruhe, Germany) and equilibrated in  $1\times$  Tris/glycine (TG) buffer (161-0734; Bio-Rad Laboratories). Separated proteins were transferred to the membrane using OmniPAGE mini vertical systems and Semi-dry Blotter (Cleaver Scientific, Warwickshire, United Kingdom) and  $10\times$  TG buffer. Protein detection was performed using the Amplified Opti-4CN Substrate Kit (1708238; Bio-Rad Laboratories), according to the manufacturer's instructions and the following antibody dilutions: NPC1 antibody (1:500, ab55706; Abcam, Cambridge, United Kingdom), Actin antibody (1:500, VMA00048; Bio-Rad AbD Serotec, Puchheim, Germany), goat anti-mouse-horse radish peroxidase (GAM-HRP, 1:1,000, STAR207P; Bio-Rad AbD Serotec).

#### TLR9 Reporter Assay

HEK-Blue hTLR9 cells, which were generated by co-transfection of the hTLR9 gene and an optimized SEAP reporter gene into HEK293 cells, were obtained from InvivoGen (hkb-htlr9; Toulouse, France). The SEAP reporter gene was placed under the control of the interferon-beta (IFN $\beta$ ) minimal promoter fused to five NF- $\kappa$ B and activator protein 1 (AP-1) binding sites. Stimulation with a TLR9 ligand activates NF- $\kappa$ B and AP-1, which induce the production of SEAP. Cells were cultivated in DMEM GlutaMAX (32430027; Gibco, Life Technologies) supplemented with 10% FCS (10270106; Gibco), 1 mM sodium pyruvate (11360070; Gibco),  $1\times$  antibiotic-antimycotic (15240062; Gibco), 10  $\mu$ g/mL Blasticidin (ant-bl-05; InvivoGen) and 100  $\mu$ g/mL Zeocin (ant-zn-1; InvivoGen). Cells were seeded at 25,000 cells per well in 96-well plates and incubated



for 20 h at 37°C and 5% CO<sub>2</sub>. Then, they were treated with ODN2006 (ttrl-2006; InvivoGen) or LNA-ASOs 05HM and 28H, with 5-fold serial dilutions, starting at a concentration of 5,000–1.6 nM. As a control, cells were treated with cell culture medium without addition of oligonucleotides. Each condition was performed in triplicate. Twenty hours after cell treatment, 100 μL Quanti-Blue (QB) Solution (rep-qbs; InvivoGen) was prepared by adding 1 mL of QB reagent and 1 mL of QB buffer to 98 mL of sterile water in a sterile glass bottle or flask. QB Solution was gently mixed and incubated for 10 min at room temperature before it was added to the sample. HEK-Blue-hTLR9 cell supernatants (20 μL per well) were harvested into a fresh 96-well plate and 180 μL QB solution was added to each well. Samples were incubated for 2 h at 37°C, and SEAP activity was determined by measurement of the optical density at 620 nm with a microplate reader.

Stably transfected HEK cells expressing a mouse Tlr9 Nf-kb luciferase reporter plasmid, kindly provided by Prof. Holger Garn, University of Marburg, were used for the murine Tlr9 reporter gene assay. Stimulation with mouse Tlr9 ligands activate Nf-kb which induces the expression of firefly luciferase (*Photinus pyralis*). HEK-mTlr9\_ Nf-kb-LUC cells (25,000/well) were plated in a white-walled, 96-well tissue-culture plate in DMEM GlutaMAX (32430027; Gibco, supplemented as described above). Twenty hours after cell seeding, the cells were treated with 5-fold serial dilutions of ODN1668 (ttrl-1668; InvivoGen) or LNA-ASO 05HM, starting at a concentration of 5,000–1.6 nM and incubated for 20 h at 37°C in the incubator. As a control, cells were treated with cell culture medium without addition of oligonucleotides. Each condition was performed in triplicate. After the incubation period, the plates were centrifuged for 5 min at 500 g, and the cell supernatants were removed. ONE-Glo EX reagent (50 μL, E8110; Promega) was added to each well, and cells were lysed according to the manufacturer's instructions. Luminescence was immediately measured at 560 nm.

### Cytokine Release

PBMCs were isolated from leukapheresis products donated by three healthy individuals (Klinikum rechts der Isar, TU München, ethics commission reference: 329/16 S), by density gradient centrifugation. The leukapheresis product was diluted 1:10 with PBS (10010-023; Gibco) and carefully loaded onto 15 mL Bicolll separating solution (L6115; Biochrom, Berlin, Germany) in 50 mL Falcon tubes. Density gradient centrifugation was performed at 800 g for 20 min at room temperature with the brake turned off. Afterward, the mononuclear cell layer was collected carefully and transferred into a new 50 mL Falcon tube, and PBS was added to a final volume of 50 mL. After centrifugation at 500 g for 5 min at room temperature (brake turned on) supernatants were discarded, and cell pellets were pooled in PBS in a total volume of 50 mL. Cells were counted, divided into aliquots, and stored on liquid nitrogen for further use. PBMCs (400,000) were seeded in RPMI-1640 medium (72400-047; Gibco) supplemented with 10% FCS, 1 mM sodium pyruvate, 1× antibiotic-antimycotic, and 50 U/mL Benzoylase (70746-3; Merck, Darmstadt, Germany) per well of a 96-well plate. Afterwards, the cells were

treated with RPMI containing either oligonucleotides (5 or 20 μM ASO 05HM or 20 μM negative control Neg1) or immune stimulatory agents: 20 μM ODN2006 (ttrl-2006; InvivoGen), 10 ng/mL LPS (L4391; Sigma Aldrich, Taufkirchen, Germany), or 25 μL/mL CD3/CD28/CD2 (10970; StemCell Technologies, Inc., Grenoble, France). Each condition was performed in triplicate. Treated cells were then rested for 72 h at 37°C and 5% CO<sub>2</sub>. The third day after treatment, 96-well plates were subjected to centrifugation at 2,000 rpm for 10 min at 4°C. Cell supernatants were collected in 96-well plates. For the measurement of IFNγ secretion, 50 μL of cell supernatant was diluted with 50 μL ELISA/ELISPOT diluent. IFNγ measurement was performed with IFNγ Human Uncoated ELISA Kit from eBioscience (88-7316-88; Thermo Fisher Scientific) according to the manufacturer's protocol. For the measurement of IL6 and TNFα secretion, 50 μL of cell supernatant was diluted with 50 μL Assay Diluent A. IL-6 and TNFα measurements were performed with IL-6 and TNFα ELISA Kits, respectively, from BioLegend (Koblenz, Germany [IL6; 430505] and [TNFα; 430201]), according to the manufacturer's protocols.

### EBOV Infection Assay

All work with infectious EBOV was performed in compliance with national regulations at the BSL4 Laboratory of the Institute of Virology, Philipps-University, Marburg.

HeLa cells were pretreated in duplicate two times for 3 days by adding medium containing 10 μM of ASOs 05HM and 28H and negative control oligonucleotides Neg1, Neg1B, or S5 or medium only (mock). At 1 h prior to infection, ASOs were removed. Cells were then infected with EBOV Mayinga (NCBI accession number GenBank: AF086833.2) at an MOI of 0.01 for 3 h in the absence of ASOs. Subsequently, the cells were washed to remove unbound input virus and incubated in the presence of 10 μM of the respective ASO. At 24 h after infection, cellular RNA was isolated using the RNeasy Kit (74106; QIAGEN, Hilden, Germany). For virus quantification, EBOV L- or GP-specific primer sets and probes were used for qRT-PCR analysis.<sup>82</sup> Knockdown of *NPC1* was analyzed via qRT-PCR with *NPC1* specific primers (VHPS-6283; Real-Time Primers, Elkins Park, PA) using the QuantiTect SYBR Green RT-PCR Kit (204143; QIAGEN). Ct values were normalized to the internal control α-tubulin (2<sup>-ΔCt</sup>), and the fold change over mock was calculated using the 2<sup>-ΔΔCt</sup> method.<sup>83</sup>

### Statistical Analysis

GraphPad Prism 7.04 Software was used for statistical calculations. The efficacy of the ASOs was assessed by one-way ANOVA followed by Dunnett's multiple-comparison test, to contrast the treatment groups (including control ASOs) with mock control. Differences were considered statistically significant when  $p < 0.05$ .

### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.omtn.2019.04.018>.

## AUTHOR CONTRIBUTIONS

The study design was developed by A.S., E.D., M.K., M.H., M.E., S.B., and F.J. The bioinformatic design of the ASOs was created by S.M. The experiments were executed by A.S., E.D., M.K., M.H., T.T., and R.K. Data were evaluated by A.S., M.K., M.H., and E.D. The manuscript was written by A.S., E.D., S.M., and F.J.

## CONFLICTS OF INTEREST

A.S., S.M., M.H., T.T., R.K. and F.J. are/were employees of Secarna Pharmaceuticals & Co. KG (Planegg, Germany). The rest of the authors declare no competing interests.

## ACKNOWLEDGMENTS

This work was supported by “Projekträger Bayern” (Bayerisches Forschungsprogramm “Bio- und Gentechnologie” (BayBIO); grant FKZ BIO-1505-0004). We thank Holger Garn (Marburg, Germany) for kindly providing us with the HEK cells expressing a mouse TLR9 NF- $\kappa$ B luciferase reporter plasmid. We also thank Lisa Hinterwimmer and Monika Schell for excellent technical support.

## REFERENCES

- Feldmann, H., Jones, S., Klenk, H.-D., and Schnittler, H.-J. (2003). Ebola virus: from discovery to vaccine. *Nat. Rev. Immunol.* 3, 677–685.
- Geisbert, T.W., and Jahrling, P.B. (2004). Exotic emerging viral diseases: progress and challenges. *Nat. Med.* 10 (12, Suppl), S110–S121.
- Kuhn, J.H., Becker, S., Ebihara, H., Geisbert, T.W., Johnson, K.M., Kawaoka, Y., Lipkin, W.L., Negro, A.L., Netesov, S.V., Nichol, S.T., et al. (2010). Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. *Arch. Virol.* 155, 2083–2103.
- Working Group on Civilian Biodefense (2002). Hemorrhagic fever viruses as biological weapons: medical and public health management. *JAMA* 287, 2391–2405.
- Jaax, N., Jahrling, P., Geisbert, T., Geisbert, J., Steele, K., McKee, K., Nagley, D., Johnson, E., Jaax, G., and Peters, C. (1995). Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. *Lancet* 346, 1669–1671.
- Johnson, E., Jaax, N., White, J., and Jahrling, P. (1995). Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. *Int. J. Exp. Pathol.* 76, 227–236.
- Lee, J.E., Fusco, M.L., Hessel, A.J., Oswald, W.B., Burton, D.R., and Saphire, E.O. (2008). Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. *Nature* 454, 177–182.
- White, J.M., Delos, S.E., Brecher, M., and Schornberg, K. (2008). Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. *Crit. Rev. Biochem. Mol. Biol.* 43, 189–219.
- Falasca, L., Agrati, C., Petrosillo, N., Di Caro, A., Capobianchi, M.R., Ippolito, G., and Piacentini, M. (2015). Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. *Cell Death Differ.* 22, 1250–1259.
- Carette, J.E., Raaben, M., Wong, A.C., Herbert, A.S., Obernosterer, G., Mulherkar, N., Kuehne, A.I., Kranzusch, P.J., Griffin, A.M., Ruthel, G., et al. (2011). Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. *Nature* 477, 340–343.
- Côté, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C.M., Hensley, L., Li, Q., Ory, D., Chandran, K., and Cunningham, J. (2011). Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. *Nature* 477, 344–348.
- Krishnan, A., Miller, E.H., Herbert, A.S., Ng, M., Ndungo, E., Whelan, S.P., Dye, J.M., and Chandran, K. (2012). Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor. *Viruses* 4, 2471–2484.
- Miller, E.H., Obernosterer, G., Raaben, M., Herbert, A.S., Deffieu, M.S., Krishnan, A., Ndungo, E., Sandesara, R.G., Carette, J.E., Kuehne, A.I., et al. (2012). Ebola virus entry requires the host-programmed recognition of an intracellular receptor. *EMBO J.* 31, 1947–1960.
- Cruz, J.C., Sugii, S., Yu, C., and Chang, T.-Y. (2000). Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol. *J. Biol. Chem.* 275, 4013–4021.
- Infante, R.E., Wang, M.L., Radhakrishnan, A., Kwon, H.J., Brown, M.S., and Goldstein, J.L. (2008). NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. *Proc. Natl. Acad. Sci. USA* 105, 15287–15292.
- Carstea, E.D., Morris, J.A., Coleman, K.G., Loftus, S.K., Zhang, D., Cummings, C., Gu, J., Rosenfeld, M.A., Pavan, W.J., Krizman, D.B., et al. (1997). Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. *Science* 277, 228–231.
- Naureckiene, S., Sleat, D.E., Lackland, H., Fensom, A., Vanier, M.T., Wattiaux, R., Jadot, M., and Lobel, P. (2000). Identification of HE1 as the second gene of Niemann-Pick C disease. *Science* 290, 2298–2301.
- Herbert, A.S., Davidson, C., Kuehne, A.I., Bakken, R., Braigen, S.Z., Gunn, K.E., Whelan, S.P., Brummelkamp, T.R., Twenhafel, N.A., Chandran, K., et al. (2015). Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. *MBio* 6, e00565–15.
- Viney, N.J., van Capelleveen, J.C., Geary, R.S., Xia, S., Tami, J.A., Yu, R.Z., Marcovina, S.M., Hughes, S.G., Graham, M.J., and Crooke, R.M. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet* 388, 2239–2253.
- Janssen, H.L.A., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., et al. (2013). Treatment of HCV infection by targeting microRNA. *N. Engl. J. Med.* 368, 1685–1694.
- Schluep, T., Lickliter, J., Hamilton, J., Lewis, D.L., Lai, C.-L., Lau, J.Y., Locarnini, S.A., Gish, R.G., and Given, B.D. (2017). Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. *Clin. Pharmacol. Drug Dev.* 6, 350–362.
- Dias, N., and Stein, C.A. (2002). Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. *Eur. J. Pharm. Biopharm.* 54, 263–269.
- Eckstein, F. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. *Nucleic Acid Ther.* 24, 374–387.
- Hagedorn, P.H., Persson, R., Funder, E.D., Albæk, N., Diemer, S.L., Hansen, D.J., Møller, M.R., Papargyri, N., Christiansen, H., Hansen, B.R., et al. (2018). Locked nucleic acid: modality, diversity, and drug discovery. *Drug Discov. Today* 23, 101–114.
- Frieden, M., and Ørum, H. (2008). Locked nucleic acid holds promise in the treatment of cancer. *Curr. Pharm. Des.* 14, 1138–1142.
- Stein, C.A., Hansen, J.B., Lai, J., Wu, S., Voskresenskiy, A., Høg, A., Worm, J., Hedtjörn, M., Souleimanian, N., Miller, P., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. *Nucleic Acids Res.* 38, e3.
- Jaschinski, F., Korhonen, H., and Janicot, M. (2015). Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF- $\beta$ ) Isoform mRNAs for the Treatment of Solid Tumors. *Methods Mol. Biol.* 1317, 137–151.
- Vollmer, J., Jepsen, J.S., Uhlmann, E., Schetter, C., Jurk, M., Wader, T., Wüllner, M., and Krieg, A.M. (2004). Modulation of CpG Oligodeoxynucleotide-Mediated Immune Stimulation by Locked Nucleic Acid. *Oligonucleotides* 14, 23–31.
- Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., and Panoskaltis, N. (2006). Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. *N. Engl. J. Med.* 355, 1018–1028.
- Coch, C., Lück, C., Schwickart, A., Putschli, B., Renn, M., Höller, T., Barchet, W., Hartmann, G., and Schlee, M. (2013). A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA. *PLoS ONE* 8, e71057.
- Ren, T., Wen, Z.-K., Liu, Z.-M., Qian, C., Liang, Y.-J., Jin, M.-L., Cai, Y.Y., and Xu, L. (2008). Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. *Cancer Invest.* 26, 448–455.

32. Vetter, P., Fischer, W.A., 2nd, Schibler, M., Jacobs, M., Bausch, D.G., and Kaiser, L. (2016). Ebola Virus Shedding and Transmission: Review of Current Evidence. *J. Infect. Dis.* *214* (Suppl 3), S177–S184.
33. Easton, V., McPhillie, M., Garcia-Dorival, I., Barr, J.N., Edwards, T.A., Foster, R., Fishwick, C., and Harris, M. (2018). Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. *Antiviral Res.* *156*, 46–54.
34. Kadanali, A. (2015). .. An overview of Ebola virus disease, 2 (North. Clin. Istanbul), pp. 81–86.
35. Bray, M., and Paragas, J. (2002). Experimental therapy of filovirus infections. *Antiviral Res.* *54*, 1–17.
36. Feldmann, H., Jones, S.M., Schnittler, H.-J., and Geisbert, T. (2005). Therapy and prophylaxis of Ebola virus infections. *Curr. Opin. Investig. Drugs* *6*, 823–830.
37. Mühlberger, E. (2007). Filovirus replication and transcription. *Future Virol.* *2*, 205–215.
38. Kitson, J.D.A., Kamola, P.J., and Kane, L. (2018). Hybridization-Dependent Effects: The Prediction, Evaluation, and Consequences of Unintended Target Hybridization. In *Oligonucleotide-Based Drugs and Therapeutics*, N. Ferrari and R. Seguin, eds. (John Wiley & Sons), pp. 191–225.
39. Crooke, S.T. (2017). Molecular Mechanisms of Antisense Oligonucleotides. *Nucleic Acid Ther.* *27*, 70–77.
40. Castanotto, D., Lin, M., Kowolik, C., Wang, L., Ren, X.-Q., Soifer, H.S., Koch, T., Hansen, B.R., Oerum, H., Armstrong, B., et al. (2015). A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. *Nucleic Acids Res.* *43*, 9350–9361.
41. Tse, M.T. (2012). Nuclear RNA more susceptible to knockdown: Antisense therapeutics. *Nat. Rev. Drug Discov.* *11*, 674.
42. Chery, J., Petri, A., Wagschal, A., Lim, S.-Y., Cunningham, J., Vasudevan, S., Kauppinen, S., and Näär, A.M. (2018). Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1. *Nucleic Acid Ther.* *28*, 273–284.
43. Nyakatura, E.K., Frei, J.C., and Lai, J.R. (2015). Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. *ACS Infect. Dis.* *1*, 42–52.
44. Amritraj, A., Wang, Y., Revett, T.J., Vergote, D., Westaway, D., and Kar, S. (2013). Role of cathepsin D in U18666A-induced neuronal cell death: potential implication in Niemann-Pick type C disease pathogenesis. *J. Biol. Chem.* *288*, 3136–3152.
45. Dieckmann, A., Hagedorn, P.H., Burki, Y., Brüggmann, C., Berrera, M., Ebeling, M., Singer, T., and Schuler, F. (2018). A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides. *Mol. Ther. Nucleic Acids* *10*, 45–54.
46. Geary, R.S., Norris, D., Yu, R., and Bennett, C.F. (2015). Pharmacokinetics, bio-distribution and cell uptake of antisense oligonucleotides. *Adv. Drug Deliv. Rev.* *87*, 46–51.
47. Stein, C.A., and Castanotto, D. (2017). FDA-Approved Oligonucleotide Therapies in 2017. *Mol. Ther.* *25*, 1069–1075.
48. Shen, X., and Corey, D.R. (2018). Chemistry, mechanism and clinical status of anti-sense oligonucleotides and duplex RNAs. *Nucleic Acids Res.* *46*, 1584–1600.
49. Juliano, R.L. (2018). Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't. *Nucleic Acid Ther.* *28*, 166–177.
50. Crooke, S.T., Wang, S., Vickers, T.A., Shen, W., and Liang, X.-H. (2017). Cellular uptake and trafficking of antisense oligonucleotides. *Nat. Biotechnol.* *35*, 230–237.
51. Lindow, M., Vormlocher, H.-P., Riley, D., Kornbrust, D.J., Burchard, J., Whiteley, L.O., Kamens, J., Thompson, J.D., Nochur, S., Younis, H., et al. (2012). Assessing unintended hybridization-induced biological effects of oligonucleotides. *Nat. Biotechnol.* *30*, 920–923.
52. Javanbakht, H., Mueller, H., Walther, J., Zhou, X., Lopez, A., Pattupara, T., Blaising, J., Pedersen, L., Albæk, N., Jackerott, M., et al. (2018). Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. *Mol. Ther. Nucleic Acids* *11*, 441–454.
53. Branda, R.F., Moore, A.L., Mathews, L., McCormack, J.J., and Zon, G. (1993). Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. *Biochem. Pharmacol.* *45*, 2037–2043.
54. Pisetsky, D.S., and Reich, C.F. (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. *Life Sci.* *54*, 101–107.
55. Zhao, Q., Tamsamani, J., Iadarola, P.L., Jiang, Z., and Agrawal, S. (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. *Biochem. Pharmacol.* *51*, 173–182.
56. Weiner, G.J., Liu, H.M., Wooldridge, J.E., Dahle, C.E., and Krieg, A.M. (1997). Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. *Proc. Natl. Acad. Sci. USA* *94*, 10833–10837.
57. Sanjaya, A., Elder, J.R., and Shah, D.H. (2017). Identification of new CpG oligodeoxynucleotide motifs that induce expression of interleukin-1 $\beta$  and nitric oxide in avian macrophages. *Vet. Immunol. Immunopathol.* *192*, 1–7.
58. Vollmer, J., Weeratna, R.D., Jurk, M., Samulowitz, U., McCluskie, M.J., Payette, P., Davis, H.L., Schetter, C., and Krieg, A.M. (2004). Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. *Immunology* *113*, 212–223.
59. Roberts, T.L., Sweet, M.J., Hume, D.A., and Stacey, K.J. (2005). Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. *J. Immunol.* *174*, 605–608.
60. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000). A Toll-like receptor recognizes bacterial DNA. *Nature* *408*, 740–745.
61. Barchet, W., Wimmenauer, V., Schlee, M., and Hartmann, G. (2008). Accessing the therapeutic potential of immunostimulatory nucleic acids. *Curr. Opin. Immunol.* *20*, 389–395.
62. Bauer, S., Kirschning, C.J., Häcker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H., and Lipford, G.B. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. *Proc. Natl. Acad. Sci. USA* *98*, 9237–9242.
63. Kadowaki, N., Ho, S., Antonenko, S., Malefyt, R.W., Kastelein, R.A., Bazan, F., and Liu, Y.J. (2001). Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J. Exp. Med.* *194*, 863–869.
64. Krieg, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. *Annu. Rev. Immunol.* *20*, 709–760.
65. Uhlmann, E., and Vollmer, J. (2003). Recent advances in the development of immunostimulatory oligonucleotides. *Curr. Opin. Drug Discov. Devel.* *6*, 204–217.
66. Olejnik, J., Forero, A., Deflubé, L.R., Hume, A.J., Manhart, W.A., Nishida, A., Marzi, A., Katze, M.G., Ebihara, H., Rasmussen, A.L., et al. (2017). Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages. *J. Virol.* *91*, e00179–17.
67. Geisbert, T.W., Hensley, L.E., Larsen, T., Young, H.A., Reed, D.S., Geisbert, J.B., Scott, D.P., Kagan, E., Jahrling, P.B., and Davis, K.J. (2003). Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. *Am. J. Pathol.* *163*, 2347–2370.
68. Baseler, L., Chertow, D.S., Johnson, K.M., Feldmann, H., and Morens, D.M. (2017). The Pathogenesis of Ebola Virus Disease. *Annu. Rev. Pathol.* *12*, 387–418.
69. Dahlmann, F., Biedenkopf, N., Babler, A., Jahnhen-Dechent, W., Karsten, C.B., Gnirß, K., Schneider, H., Wrensch, F., O'Callaghan, C.A., Bertram, S., et al. (2015). Analysis of Ebola Virus Entry Into Macrophages. *J. Infect. Dis.* *212* (Suppl 2), S247–S257.
70. Agrawal, S., Tang, J.Y., and Brown, D.M. (1990). Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. *J. Chromatogr. A* *509*, 396–399.
71. Vaillant, A., Juteau, J.-M., Lu, H., Liu, S., Lackman-Smith, C., Ptak, R., and Jiang, S. (2006). Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. *Antimicrob. Agents Chemother.* *50*, 1393–1401.
72. Vaillant, A. (2016). Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. *Antiviral Res.* *133*, 32–40.

73. Abe, T., Mizuta, T., Hatta, T., Miyano-Kurosaki, N., Fujiwara, M., Takai, K., Shigeta, S., Yokota, T., and Takaku, H. (2001). Antisense therapy of influenza. *Eur. J. Pharm. Sci.* *13*, 61–69.
74. Guzman, E.M., Cheshenko, N., Shende, V., Keller, M.J., Goyette, N., Juteau, J.-M., Boivin, G., Vaillant, A., and Herold, B.C. (2007). Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. *Antivir. Ther. (Lond.)* *12*, 1147–1156.
75. Lee, A.M., Rojek, J.M., Gundersen, A., Ströher, U., Juteau, J.-M., Vaillant, A., and Kunz, S. (2008). Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. *Virology* *372*, 107–117.
76. Bernstein, D.L., Goyette, N., Cardin, R., Kern, E.R., Boivin, G., Ireland, J., Juteau, J.M., and Vaillant, A. (2008). Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. *Antimicrob. Agents Chemother.* *52*, 2727–2733.
77. Cardin, R.D., Bravo, F.J., Sewell, A.P., Cummins, J., Flamand, L., Juteau, J.-M., Bernstein, D.L., and Vaillant, A. (2009). Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. *Viol. J.* *6*, 214.
78. Beniac, D.R., and Booth, T.F. (2017). Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution. *Sci. Rep.* *7*, 46374.
79. Prüfer, K., Stenzel, U., Dannemann, M., Green, R.E., Lachmann, M., and Kelso, J. (2008). PatMaN: rapid alignment of short sequences to large databases. *Bioinformatics* *24*, 1530–1531.
80. Tolstrup, N., Nielsen, P.S., Kolberg, J.G., Frankel, A.M., Vissing, H., and Kauppinen, S. (2003). OligoDesign: Optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. *Nucleic Acids Res.* *31*, 3758–3762.
81. Burdick, A.D., Sciabola, S., Mantena, S.R., Hollingshead, B.D., Stanton, R., Warneke, J.A., Zeng, M., Martsen, E., Medvedev, A., Makarov, S.S., et al. (2014). Sequence motifs associated with hepatotoxicity of locked nucleic acid: modified antisense oligonucleotides. *Nucleic Acids Res.* *42*, 4882–4891.
82. Gibb, T.R., Norwood, D.A., Jr., Woollen, N., and Henchal, E.A. (2001). Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan. *J. Clin. Microbiol.* *39*, 4125–4130.
83. Schmittgen, T.D., and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* *3*, 1101–1108.

OMTN, Volume 16

## Supplemental Information

**Anti-Niemann Pick C1 Single-Stranded**

**Oligonucleotides with Locked Nucleic Acids**

**Potently Reduce Ebola Virus Infection *In Vitro***

**Anne Sadewasser, Erik Dietzel, Sven Michel, Michael Klüver, Markus Helfer, Tamara Thelemann, Richard Klar, Markus Eickmann, Stephan Becker, and Frank Jaschinski**

**Supplemental Figures**  
**Fig. S1**






Fig. S2



## Supplemental Figure Legends

**Fig. S1. EBOV L-specific ASO shows specific inhibition in transfection-based assays, but not during EBOV infection.** (A) After seeding Huh7 cells, triplicate wells were treated with serial dilutions of EBOV L-specific ASO or negative control Neg1. The next day, cells were used for EBOV minigenome assay and transfected with the corresponding plasmids (details see supplemental methods). Three hours post transfection, medium was changed to ASO-containing medium. 24 hours post transfection cells were lysed and used for renilla luciferase assay. The positive control was set to 100 % (n=1). Displayed are means with standard deviations of triplicate wells. (B) After seeding of Huh7 cells, duplicate wells were treated with EBOV L-specific ASO or negative control Neg1. The next day, cells were used for EBOV trVLP Assay (producer cell setting) and transfected with the corresponding plasmids (details see supplemental methods). For normalization of transfection efficiency, a firefly luciferase reporter was added. Four hours post transfection, medium was changed to ASO-containing medium. 24 hours post transfection cells were lysed and used for renilla and firefly luciferase assay. Renilla reporter signals were normalized by use of firefly signals and the positive control was set to 100 % (n=1). Displayed are means with standard deviations of duplicate wells. (C) Huh7 cells were pre-incubated with a serial dilution of EBOV L-specific ASO or negative control Neg1. The next day, cells were infected with EBOV Makona with an MOI of 0.01 for 1 hour. After infection, cells were washed to remove unbound virus and ASO-containing medium was added. 24 hours post infection, cells were harvested and RNA was isolated. RNA samples were used for EBOV L-specific RT-qPCR and the copies/well were calculated using an EBOV-specific standard curve (n=1). (D) Shown are treatments with different concentrations of EBOV L-specific ASO and different conditions like pretreatment with ASO, transfection with ASO or transfection with plasmids. Huh7 cells were pre-incubated with dilutions of EBOV L-specific ASO or negative control Neg1. The next day, cells were transfected with ASOs or empty mCherry plasmid as a control. Five hours post transfection, medium was changed to ASO-containing medium. 24 hours post transfection, cells were infected with EBOV rgZ-GFP with an MOI of 0.01 for 1 hour. After infection, cells were washed to remove unbound virus and ASO-containing medium was added. 24 hours post infection cells were harvested and RNA was isolated. RNA samples were used for EBOV NP-specific RT-qPCR and the copies/well were calculated using an EBOV specific standard curve (n=1).

**Fig. S2. PTO-backbone mediated inhibition of non-NPC1-specific ASOs Neg1, Neg1b and S5 compared to NPC1-specific ASO 28H.** HeLa cells pretreated with the respective ASO were infected with EBOV at an MOI of 0.01. At 1 d p.i., *NPC1* (A) and EBOV (B) levels were quantified by RT-qPCR and normalized to the internal control  $\alpha$ -tubulin. Shown is the fold change compared to untreated control (set as 100), which was calculated using the  $2^{-\Delta\Delta C_t}$  method. Error bars show standard deviations (n=3, each in duplicates). Duplicates were labeled with identical symbol shapes. ANOVA test was used to test for significant differences and P values were determined using Dunnett's test in GraphPad Prism 7.04 Software.



## Supplemental Tables

Table S1

**Antisense oligonucleotides targeting host factor Niemann-Pick C1 as well as non-specific control oligonucleotides Neg1, Neg1b and S5.** Depicted are Name of ASO, mRNA binding sequence, position on mRNA, ASO length as well as ASO sequence and modification: LNA (+) and/or phosphorothioate (\*). Human-specific ASOs (H) as well as cross-reactive ASOs targeting both, human and murine *NPC1* (HM), were selected.

Name	mRNA binding sequence	Position	Length	Sequence
01H	AACCAGCCGAACGCCGC	229	17	+G*+C*+G*G*C*G*T*T*C*G*G*C*T*G*+G*+T*+T
02H	ACCAGCCGAACGCCGCC	230	17	+G*+G*+C*G*G*C*G*T*T*C*G*G*C*T*+G*+G*+T
03H	GCATGACCGCTCGCGGC	273	17	+G*C*C*G*C*G*A*G*C*G*G*T*C*A*T*+G*+C
04HM	TGTTTGGTATGGAGAGT	349	17	+A*+C*+T*C*T*C*C*A*T*A*C*C*A*A*+A*+C*+A
05HM	GGAGAGTGTGGAATTGC	359	17	+G*+C*+A*A*T*T*C*C*A*C*A*C*T*C*+T*+C*+C
06HM	CTTAGTGCAGGAACT	445	15	+A*+G*+T*T*C*C*T*G*C*A*C*T*+A*+A*+G
07HM	ATGTACAATGCCTGCCG	740	17	+C*+G*+G*C*A*G*G*C*A*T*T*G*T*+A*+C*+A*+T
08HM	GCCACCAACTGGATTGA	830	17	+T*+C*A*+A*T*C*C*A*G*T*T*G*G*T*G*G*+C
09HM	TGTATGTCATCATGTGG	1077	17	+C*+C*+A*C*A*T*G*A*T*G*A*C*A*T*+A*+C*+A
10HM	GTATGTCATCATGTGG	1078	16	+C*+C*+A*C*A*T*G*A*T*G*A*C*A*+T*+A*+C
11H	GTATGCCGATTACCAC	1789	16	+G*+T*+G*G*T*A*A*T*C*G*G*C*A*+T*+A*+C
12H	CGATTACCACACGCAC	1795	16	+G*+T*+G*C*G*T*G*T*G*G*T*A*A*+T*+C*+G
13HM	CGTGGCTTGTGTTGG	1902	15	+C*+C*A*A*C*A*C*A*A*G*C*+C*+A*+C*+G
14HM	TGGACAACATCTTCA	2370	15	+T*+G*+A*+A*G*A*T*G*T*T*G*T*+C*+C*+A
15HM	TTCGCTTCTTCAAAA	2727	15	+T*+T*+T*T*G*A*A*G*A*A*G*C*+G*+A*+A
16HM	CAGAACATGGTGTGCCG	2987	17	+C*+C*+G*C*A*C*A*C*C*A*T*G*T*T*C*+T*+G
17HM	ACATGGTGTGCGGCG	2991	15	+C*+G*+C*C*G*C*A*C*A*C*C*A*+T*+G*+T
18HM	GTGTGCGGCGGCATG	2996	15	+C*+A*+T*G*C*C*G*C*C*G*C*A*+C*+A*+C
19H	AGATATTTAACGCGGC	3039	16	+G*+C*+C*G*C*G*T*T*A*A*A*T*A*+T*+C*+T
20H	GATATTTAACGCGGC	3040	15	+G*+C*+C*G*C*G*T*T*A*A*A*T*+A*+T*+C
21HM	CCTCGTCCTGGATCGA	3090	16	+T*+C*G*A*T*C*C*A*G*G*A*C*G*A*+G*+G
22HM	TTCATGACCTACCACAC	3386	17	+G*+T*+G*T*G*G*T*A*G*G*T*C*A*T*+G*+A*+A
23HM	TCATGACCTACCACAC	3387	16	+G*+T*+G*T*G*G*T*A*G*G*T*C*A*+T*+G*+A
24H	GGCGGATATTTCTGG	3593	16	+C*+C*+A*G*A*A*A*T*A*T*C*G*C*+G*+C*+C
25H	ACATAACCAGAGCGTT	3783	16	+A*+A*+C*G*C*T*C*T*G*G*T*T*A*+T*+G*+T
26HM	GTGGAATCACACTTAC	3873	16	+G*+T*+A*A*G*T*G*T*G*A*T*T*C*C*+A*+C
27HM	ACTCAGTTACATAGG	4015	15	+C*C*T*A*T*G*T*A*A*C*T*G*+A*+G*+T
28H	AGCGCGAACGGCTTCTA	4086	17	+T*+A*+G*A*A*G*C*C*G*T*T*C*G*C*+G*+C*+T
29H	TCGGTCGGTTTACCACT	4151	17	+A*+G*+T*G*G*T*A*A*A*C*C*G*A*C*+C*+G*+A

30H	CGGTCGGTTTACCACT	4152	16	+A*+G*+T*G*G*T*A*A*A*C*C*G*A*+C*+C*+G
31H	TTGAACGTAGCGCCTG	4240	16	+C*+A*+G*G*C*G*C*T*A*C*G*T*T*+C*+A**+A
32HM	TCAGAATGTTGTAGGCC	4609	17	+G*+G*C*C*T*A*C*A*A*C*A*T*T*C*+T*+G**+A
33HM	ATGTTGTAGGCCTCATT	4614	17	+A*+A*T*G*A*G*G*C*C*T*A*C*A*+A*+C*+A*+T
34HM	TGTAGGCCTCATTAGA	4618	16	+T*+C*+T*A*A*T*G*A*G*G*C*C*T*+A*+C*+A
35HM	TGTAGGCCTCATTAGAG	4618	17	+C*+T*+C*T*A*A*T*G*A*G*G*C*C*T*+A*+C*+A
36HM	GTAGGCCTCATTAGAGC	4619	17	+G*+C*+T*C*T*A*A*T*G*A*G*G*C*C*+T*+A**+C
Neg1	N/A	N/A	18	+C*+G*+T*T*T*A*G*G*C*T*A*T*G*T*A*+C*+T*+T
Neg1b	N/A	N/A	17	+G*+T*T*T*A*G*G*C*T*A*T*G*T*A*+C*+T*+T
S5	N/A	N/A	17	+T*+T*+A*T*G*T*C*C*G*G*T*T*A*T*+T*+T*+C

## Supplemental Methods

### EBOV minigenome assay and EBOV trVLP assay (producer cell setting)

Huh7 (human hepatoma) cells were seeded in 12-well or 96-well format in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher, USA, no. 21969-035) with penicillin and streptomycin 50 U/ml (Thermo Fisher, USA, no. 15070063), 2 mM glutamine (Gibco®, Thermo Fisher, USA, no. 25030024) and 10 % fetal bovine serum (Thermo Fisher, USA, no. 10270-106) at 37 °C and 5 % CO<sub>2</sub> for 70 % confluency next day. Three hours post seeding, cells were treated with EBOV L-specific ASO or negative control Neg1. The EBOV L-specific ASO consists of the following sequence: +A\*+T\*+A\*A\*G\*G\*C\*A\*A\*T\*T\*T\*+T\*+C\*+C (+, LNA; \*, phosphorothioate). The next day, EBOV minigenome assay or trVLP assay (producer cell setting) was performed as described earlier [1,2]. Huh7 cells were transfected using TransIT-LT1 (Mirus Bio LLC, USA, no. MIR2306) with a plasmid containing an EBOV-specific minigenome encoding a renilla luciferase under control of a T7 promoter, a T7 polymerase as well as plasmids encoding viral proteins EBOV NP, VP35, VP30 and L (minigenome assay) or EBOV NP, VP35, VP30, L, VP24, VP40 and GP (trVLP assay, producer cell setting) A firefly luciferase reporter (Promega, USA, no. pGL4.13) was used for normalization, if technically possible. 3-4 hours post transfection, medium was changed to ASO-containing medium. 24 hours post transfection cells were lysed and used for luciferase assay (pjk, Germany). The positive control was set to 100 %.

### EBOV infection assay

All work with infectious EBOV was performed in compliance with national regulations at the BSL4 laboratory of the Institute of Virology, Philipps-University Marburg.

Huh7 cells were pretreated with EBOV-specific ASO or negative control Neg1 at 2-5 hours after seeding. Oligonucleotides were either simply added to the cell culture medium or cells were transfected with ASOs. The next day, cells were infected with EBOV Makona or rgEBOV-eGFP [3,4] at an MOI of 0.01 for 1 hours in the absence of ASOs. Then, cells were washed to remove unbound virus and incubated in presence of ASO-containing medium. At 24 hours post infection, cells were harvested, and RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany; no. 74106). Viral genome copies/well were determined using EBOV L- or NP-specific primers and probes for RT-qPCR analysis [5] as well as an EBOV-specific standard curve.

## Supplemental References

- [1] Mühlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. *J Virol* 1999;73:2333–42.
- [2] Hoenen T, Groseth A, Kolesnikova L, Theriault S, Ebihara H, Hartlieb B, et al. Infection of Naive Target Cells with Virus-Like Particles: Implications for the Function of Ebola Virus VP24. *Journal of Virology* 2006;80:7260–4. doi:10.1128/JVI.00051-06.
- [3] Hoenen T, Groseth A, Callison J, Takada A, Feldmann H. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. *Antiviral Research* 2013;99:207–13. doi:10.1016/j.antiviral.2013.05.017.
- [4] Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, Hensley LE, et al. In Vitro and In Vivo Characterization of Recombinant Ebola Viruses Expressing Enhanced Green Fluorescent Protein. *The Journal of Infectious Diseases* 2007;196:S313–22. doi:10.1086/520590.
- [5] Gibb TR, Norwood DA, Woollen N, Henschal EA. Development and Evaluation of a Fluorogenic 5' Nuclease Assay To Detect and Differentiate between Ebola Virus Subtypes Zaire and Sudan. *Journal of Clinical Microbiology* 2001;39:4125–30. doi:10.1128/JCM.39.11.4125-4130.2001.